Skip to main content Accessibility help
×
Home
Hostname: page-component-55597f9d44-n4bck Total loading time: 0.353 Render date: 2022-08-08T08:44:33.901Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia

Published online by Cambridge University Press:  20 April 2022

Preethi Patel*
Affiliation:
Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio
Abhishek Deshpande
Affiliation:
Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio
Pei-Chun Yu
Affiliation:
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
Peter B. Imrey
Affiliation:
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
Peter K. Lindenauer
Affiliation:
Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School–Baystate, Springfield, Massachusetts Department of Medicine, University of Massachusetts Medical School–Baystate, Springfield, Massachusetts
Marya D. Zilberberg
Affiliation:
EviMed Research Group, Goshen, Massachusetts
Sarah Haessler
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Massachusetts Medical School–Baystate, Springfield, Massachusetts
Michael B. Rothberg
Affiliation:
Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio
*
Author for correspondence: Preethi Patel, E-mail: patelp3@ccf.org

Abstract

Objective:

Clostridioides difficile infection (CDI) is the most common cause of gastroenteritis, and community-acquired pneumonia (CAP) is the most common infection treated in hospitals. American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) CAP guidelines recommend empiric therapy with a respiratory fluoroquinolone or cephalosporin plus macrolide combination, but the CDI risk of these regimens is unknown. We examined the association between each antibiotic regimen and the development of hospital-onset CDI.

Methods:

We conducted a retrospective cohort study using data from 638 US hospitals contributing administrative including 177 also contributing microbiologic data to Premier, Inc. We included adults admitted with pneumonia and discharged from July 2010 through June 2015 with a pneumonia diagnosis code who received ≥3 days of either empiric regimen. Hospital-onset CDI was defined by a diagnosis code not present on admission and positive laboratory test on day 4 or later or readmission for CDI. Mixed propensity-weighted multiple logistic regression was used to estimate the associations of CDI with antibiotic regimens.

Results:

Our sample included 58,060 patients treated with either cephalosporin plus macrolide (36,796 patients) or a fluoroquinolone alone (21,264 patients) and with microbiological data; 127 (0.35%) patients who received cephalosporin plus macrolide and 65 (0.31%) who received a fluoroquinolone developed CDI. After adjustment for patient demographics, comorbidities, risk factors for antimicrobial resistance, and hospital characteristics, CDI risks were similar for fluoroquinolones versus cephalosporin plus macrolide (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.70–1.38).

Conclusion:

Among patients with CAP at US hospitals, CDI was uncommon, occurring in ∼0.33% of patients. We did not detect a significant association between the choice of empiric guideline recommended antibiotic therapy and the development of CDI.

Type
Original Article
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Leffler, DA, Lamont, JT. Clostridium difficile infection. N Engl J Med 2015;372:15391548.CrossRefGoogle ScholarPubMed
Lofgren, ET, Cole, SR, Weber, DJ, et al. Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay. Epidemiology 2014;25:570575.CrossRefGoogle ScholarPubMed
Lessa, FC, Mu, Y, Bamberg, WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825834.CrossRefGoogle ScholarPubMed
Pfuntner, A, Wier, LM, Stocks, C. Most frequent conditions in US hospitals, 2011: statistical brief #162. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality; 2006.Google Scholar
Becerra, MB, Becerra, BJ, Banta, JE, et al. Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the nationwide inpatient sample. BMC Infect Dis 2015;15:254.CrossRefGoogle ScholarPubMed
Brown, KA, Khanafer, N, Daneman, N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013;57:23262332.CrossRefGoogle ScholarPubMed
Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881891.CrossRefGoogle ScholarPubMed
Gopal Rao, G, Mahankali Rao, CS, Starke, I. Clostridium difficile–associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam–based therapy. J Antimicrob Chemother 2003;51:697701.CrossRefGoogle ScholarPubMed
Gaynes, R, Rimland, D, Killum, E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640645.CrossRefGoogle Scholar
Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273280.CrossRefGoogle Scholar
Pepin, J, Saheb, N, Coulombe, MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:12541260.CrossRefGoogle ScholarPubMed
Chalmers, JD, Al-Khairalla, M, Short, PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010;65:608618.CrossRefGoogle Scholar
Premier Healthcare database: data that informs and performs. Premier website. https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf. Published 2020. Accessed March 15, 2022.Google Scholar
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1e48.CrossRefGoogle Scholar
Dubberke, ER, McMullen, KM, Mayfield, JL, et al. Hospital-associated Clostridium difficile infection: is it necessary to track community-onset disease? Infect Control Hosp Epidemiol 2009;30:332337.CrossRefGoogle ScholarPubMed
Redondo-Gonzalez, O. Validity and reliability of the minimum basic data set in estimating nosocomial acute gastroenteritis caused by rotavirus. Rev Esp Enferm Dig 2015;107:152161.Google ScholarPubMed
Dubberke, ER, Butler, AM, Yokoe, DS, et al. Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. Infect Control Hosp Epidemiol 2010;31:262268.CrossRefGoogle ScholarPubMed
Haessler, S, Lindenauer, PK, Zilberberg, MD, et al. Blood cultures versus respiratory cultures: 2 different views of pneumonia. Clin Infect Dis 2020;71:16041612.CrossRefGoogle ScholarPubMed
Eze, P, Balsells, E, Kyaw, MH, et al. Risk factors for Clostridium difficile infections—an overview of the evidence base and challenges in data synthesis. J Glob Health 2017;7:010417.CrossRefGoogle ScholarPubMed
Kwok, CS, Arthur, AK, Anibueze, CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:10111019.CrossRefGoogle ScholarPubMed
Muto, CA, Blank, MK, Marsh, JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007;45:12661273.CrossRefGoogle Scholar
Dingle, KE, Didelot, X, Quan, TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 2017;17:411421.CrossRefGoogle ScholarPubMed
Kabbani, S, Hersh, AL, Shapiro, DJ, et al. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis 2018;67:134136.CrossRefGoogle ScholarPubMed
Teng, C, Reveles, KR, Obodozie-Ofoegbu, OO, et al. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse-event reporting system. Int J Med Sci 2019;16:630635.CrossRefGoogle ScholarPubMed
Chalmers, JD, Akram, AR, Singanayagam, A, et al. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect 2016;73:4553.CrossRefGoogle ScholarPubMed
2015 Annual Report for the Emerging Infections Program for Clostridium difficile infection. Centers for Disease Control and Prevention website. https://www.cdc.gov/hai/eip/pdf/cdiff/2015-CDI-Report.pdf. Accessed March 15, 2022.Google Scholar
McLure, A, Clements, ACA, Kirk, M, et al. Clostridium difficile classification overestimates hospital-acquired infections. J Hosp Infect 2018;99:453460.CrossRefGoogle ScholarPubMed
Centers for Medicare and Medicaid Services (CMS), Health and Human Services (HHS). Medicare program; hospital inpatient prospective payment systems for acute-care hospitals and the long-term care hospital prospective payment system and fiscal year 2014 rates; quality reporting requirements for specific providers; hospital conditions of participation; payment policies related to patient status. Final rules. Fed Regist 2013;78:5049551040.Google Scholar
Cole, SR, Hernan, MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656664.CrossRefGoogle ScholarPubMed
Joffe, MM. Structural nested models, g-estimation, and the healthy worker effect: the promise (mostly unrealized) and the pitfalls. Epidemiology 2012;23:220222.CrossRefGoogle ScholarPubMed
Shinozaki, T, Suzuki, E. Understanding marginal structural models for time-varying exposures: pitfalls and tips. J Epidemiol 2020;30:377389.CrossRefGoogle ScholarPubMed
Vansteelandt, S, Joffe, M. Structural nested models and g-estimation: the partially realized promise. Statistical Science 2014;29:707–731, 725.Google Scholar
Williamson, T, Ravani, P. Marginal structural models in clinical research: when and how to use them? Nephrol Dial Transplant 2017;32 Suppl 2:ii84ii90.CrossRefGoogle Scholar
Chowdhry, V, Padhi, M, Mohanty, BB, et al. Fluoroquinolones: an under-recognized cause for delirium. J Anaesthesiol Clin Pharmacol 2015;31:410411.CrossRefGoogle ScholarPubMed
Postma, DF, van Werkhoven, CH, van Elden, LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:13121323.CrossRefGoogle ScholarPubMed
Supplementary material: File

Patel et al. supplementary material

Patel et al. supplementary material

Download Patel et al. supplementary material(File)
File 113 KB

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *